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Background: The purpose of this research was to compare the effects of niacin extended-release 
in combination with simvastatin (NER/S) versus atorvastatin monotherapy on high-density 
lipoprotein (HDL) particle number and size in patients with hyperlipidemia or dyslipidemia 
from the SUPREME study.
Methods: This was a post hoc analysis of patients (n = 137) who completed the SUPREME 
study and who had lipid particle number and size measurements at both baseline and at week 
12 by nuclear magnetic resonance spectroscopy. Following $4 weeks without lipid-modifying 
therapy (washout period), the patients received NER/S 1000/40 mg/day for 4 weeks followed by 
NER/S 2000/40 mg/day for 8 weeks, or atorvastatin 40 mg/day for 12 weeks. Median percent 
changes in HDL particle number and size from baseline to week 12 were compared between 
the NER/S and atorvastatin treatment groups using the Wilcoxon rank-sum test. Distribution 
of HDL particle subclasses at week 12 was compared between the treatment groups using the 
Cochran–Mantel–Haenszel test.
Results: Treatment with NER/S resulted in a significantly greater percent reduction in small 
HDL particle number at week 12 compared with atorvastatin monotherapy (−1.8% versus 4.2%, 
P = 0.014), and a numerically greater percent increase in large HDL particle number (102.4% 
versus 39.2%, P = 0.078) compared with atorvastatin monotherapy. A significantly greater 
percent increase in HDL particle size from baseline at week 12 was observed with NER/S 
compared with atorvastatin (6.0% versus 1.3%, P , 0.001). NER/S treatment also resulted in 
a significant shift in HDL particle size from small and medium at baseline to large at week 12 
(P , 0.0001).
Conclusion: Treatment with NER/S resulted in larger favorable changes in number and size 
of HDL particle subclasses compared with atorvastatin monotherapy, including a numerically 
greater increase in number of large HDL particles, and a significantly greater decrease in 
number of small HDL particles compared with atorvastatin monotherapy. In addition, NER/S 
treatment resulted in a significant change in HDL particle size distribution from small and 
medium to large.
Keywords: niacin, simvastatin, atorvastatin, lipoprotein particles, dyslipidemia, combination 
therapy, high-density lipoprotein
Introduction
Atherogenic dyslipidemia is highly prevalent, especially in patients with insulin 
  resistance and diabetes mellitus.1 Atherogenic dyslipidemia increases the risk for 
coronary heart disease and peripheral vascular disease, and remains a serious p ublic 
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health problem despite efforts to implement lifestyle 
modification and pharmacologic intervention using lipid-
modifying drugs.2 Atherogenic dyslipidemia is comprised 
of the so-called lipid triad, ie, elevated levels of plasma 
triglycerides, increased numbers of small, dense low-density 
lipoprotein (LDL) particles with normal or slightly elevated 
LDL cholesterol levels, and lower numbers of high-density 
lipoprotein (HDL) particles, primarily due to fewer large, 
cholesterol-rich (HDL2) particles with either no change or 
increased numbers of small, dense (HDL3) particles.3,4
Large, prospective, global, epidemiological studies have 
observed that high LDL cholesterol and low HDL cholesterol 
are among the most important predictors of future cardio-
vascular events, including myocardial infarction, ischemic 
stroke, and death.5–7 Recent studies employing lipoprotein 
subclass fractionation and measurement techniques8 have 
shown that increased numbers of LDL particles are associ-
ated with increased risk for coronary heart disease, with 
small, dense LDL particles usually having greater association 
with coronary heart disease.9 Furthermore, particle number, 
rather than LDL cholesterol levels, has been shown to be a 
better predictor of development of atherosclerotic disease 
and sustaining acute cardiovascular events.10–12 Reduced 
numbers of HDL particles independently predict coronary 
heart disease, and show a strong inverse correlation with 
risk for developing cardiovascular disease.13,14 Large HDL2 
particles appear to have an inverse association, whereas small 
HDL particle associations are more controversial, with some 
studies reporting positive associations with coronary heart 
disease prevalence,15,16 and others suggesting cardioprotective 
effects of HDL3 particles.4,17
Pharmacological interventions inducing less atherogenic 
lipid profiles are desirable in dyslipidemic patients who 
fail to respond to therapeutic lifestyle changes as the initial 
step in lipid management. Statins are the first-line medica-
tion widely prescribed to lower LDL cholesterol levels and 
lower LDL particle numbers; however, their effect on HDL 
particles is modest.18 Niacin is the most effective agent 
currently available for raising HDL cholesterol, and when 
used in combination with simvastatin, has shown a decrease 
in atherogenic particle numbers to a greater extent than 
  atorvastatin monotherapy.19 Moreover, niacin monotherapy 
has been shown to reduce risk of nonfatal myocardial infarc-
tion and stroke.20
The objective of this analysis was to compare the effects 
of niacin extended-release in combination with simvastatin 
(NER/S) versus atorvastatin monotherapy on HDL particle 
number and size in a post hoc analysis of patients with 
  hyperlipidemia or dyslipidemia from the SUPREME study 
(Study to Compare the Lipid Effects of Niacin ER and 
  Simvastatin to Atorvastatin in Subjects with Hyperlipidemia 
or Mixed Dyslipidemia).
Materials and methods
Study design
SUPREME was a prospective, randomized, open-label, 
blinded-endpoint, 12-week, multicenter clinical study in the 
US comparing the efficacy and safety of NER/S combina-
tion therapy with atorvastatin monotherapy. The study was 
approved by the institutional ethics committee and all patients 
gave written informed consent.21
The details of the SUPREME study have been described 
elsewhere.21 In brief, patients eligible for inclusion were men 
and women $21 years of age, with primary type II hyperlipi-
demia or mixed dyslipidemia (LDL cholesterol $130 mg/dL 
and ,250 mg/dL, HDL cholesterol ,40/50 mg/dL for 
men/women, and triglycerides ,350 mg/dL) following the 
National Cholesterol Education Program therapeutic lifestyle 
changes diet. Patients were required to discontinue lipid medi-
cation 4–5 weeks prior to randomization. The major exclusion 
criteria were creatine phosphokinase $3 × the upper limit of 
normal (ULN), alanine aminotransferase $1.3 × ULN, aspar-
tate aminotransferase $1.3 × ULN, calculated creatinine 
clearance ,30 mL/minute, glycosylated hemoglobin $9%, 
uric acid levels $1.3 × ULN, poorly controlled type 1 
or 2 diabetes, persistent, uncontrolled hypertension, and 
  pregnancy. Following 4 weeks of a therapeutic lifestyle 
changes diet and washout of any pretrial lipid treatment, 
eligible patients were randomized centrally in a 3:2 ratio to 
treatment arms (NER/S:atorvastatin). The dosing schedule 
was NER/S 1000/40 mg/day for 4 weeks, followed by NER/S 
2000/40 mg/day for 8 weeks; or atorvastatin 40 mg/day for 
12 weeks.
Analysis
Patients who completed the SUPREME study and had lipid 
particle concentration and size measurements at both baseline 
and at week 12 were included in this analysis. Fasting plasma 
samples were analyzed to determine lipoprotein particle size 
(diameter [nm]) and number (concentration [µmol/L]) by 
nuclear magnetic resonance spectroscopy (LipoProfile-II 
Test®, LipoScience Inc, Raleigh, NC).22,23 Differences in 
distribution of HDL particle subclasses defined as large 
(.8.8–13 nm), medium (.8.2–8.8 nm), and small (7.3–8.2) 
at week 12 were compared between treatment groups based 
on the Cochran–Mantel–Haenszel test. Median percent 
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changes in HDL particle number and size from baseline to 
week 12 were compared between treatment groups using the 
Wilcoxon rank-sum test.
Results
A total of 137 patients in the treatment groups of NER/S 
(n = 74) or atorvastatin (n = 63) were included in the   analysis. 
Baseline demographics and clinical characteristics of the 
two treatment groups were well matched. The mean age 
was 53.6 years, 43% of patients were male, and 15% of 
patients had diabetes mellitus.19 Baseline lipid/lipoprotein 
values were similar between the NER/S versus atorvastatin 
treatment groups, with mean LDL cholesterol levels of 
162.4 mg/dL versus 168.0 mg/dL, mean HDL cholesterol 
levels 39.9 mg/dL versus 37.6 mg/dL, and median triglyc-
erides 174.3 mg/dL versus 175.5 mg/dL.19
Median percent changes in HDL particle number from 
baseline following 12 weeks of treatment are shown in 
  Figure 1. NER/S combination therapy resulted in a reduction 
in small HDL particle number compared with atorvastatin 
monotherapy, and the difference in median percent change 
was statistically significant between the two treatment groups 
(−1.8% versus 4.2%, P = 0.014). The median percent change 
in the number of large HDL particles was numerically greater 
for NER/S combination therapy compared with atorvastatin 
monotherapy, although the difference did not reach statistical 
significance (102.4% versus 39.2%, P = 0.078). In addition, 
NER/S treatment resulted in a significantly greater median 
(interquartile range Q1, Q3) percent increase in HDL particle 
size from baseline, 6.0% (2.7%, 8.7%) versus 1.3% (−0.5%, 
3.0%) compared with atorvastatin (P , 0.001).
NER/S treatment resulted in a significant shift in HDL 
particle size from small and medium at baseline to large 
at week 12 (P , 0.0001, Figure 2). A higher proportion 
of patients with large HDL particles was observed at week 
12 after combination NER/S treatment (60.8%) compared 
with atorvastatin monotherapy (12.7%). Similarly, a lower 
proportion of patients with small HDL particles after NER/S 
treatment (1.4%) was observed compared with atorvastatin 
monotherapy (9.5%) at week 12.
Safety
The safety profiles of NER/S combination therapy and 
  atorvastatin monotherapy were consistent with the established 
safety profiles of these medications as reported earlier for the 
overall population from the SUPREME study.21 In the NER/S 
group, 82% of patients experienced treatment-emergent 
adverse events versus 41% of patients in the   atorvastatin 
monotherapy group (P , 0.001). The adverse event of 
  flushing primarily accounted for the higher percentage of 
patients who experienced treatment-emergent adverse events 
in the NER/S group compared with the atorvastatin group 
(66.2% versus 11.1%, P , 0.001).19
Discussion
In this post hoc analysis of patients with dyslipidemia, 
NER/S treatment resulted in larger favorable changes in anti-
atherogenic HDL particles than atorvastatin monotherapy, as 
evidenced by a significantly greater decrease in small HDL 
particle number, a numerically greater increase in large HDL 
particle number, and a significantly greater increase in HDL 
particle size. NER/S treatment also resulted in a favorable 
shift in the distribution of HDL particles from small and 
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Figure  1  Median  percent  change  in  high-density  lipoprotein  particle  number 
from baseline after 12 weeks of treatment with NER/S combination therapy or 
atorvastatin monotherapy. P value is from the Wilcoxon rank-sum test and is shown 
for significant comparison between NER/S combination therapy and atorvastatin 
monotherapy. The interquartile ranges (Q1, Q3) for the percent changes shown 
are as follows. Total HDL particles (−1.4%, 24.4%) for NER/S and (−0.6%, 15.9%) 
for atorvastatin; small HDL particles (−16.8%, 8.8%) for NER/S and (−6.3%, 17.5%) 
for atorvastatin; medium HDL particles (−74.3%, 194.3%) for NER/S and (−75.7%, 
117.8%) for atorvastatin; large HDL particles (32.2%, 176.9%) for NER/S and (4.2%, 
167.7%) for atorvastatin.
Notes: For medium HDL particles, patients with a baseline value of 0 were excluded. 
Reference values for median HDL particle concentrations were total = 30.1 µmol/L, 
small = 20.8 µmol/L, medium = 1.1 µmol/L, and large = 6.0 µmol/L (Based on in-
house data from a random set of fasting patient plasma samples sent to LipoScience 
for NMR LipoProfile® analysis in November/December, 2003). The patients are 
mainly from the southeastern US and are a mix of primary prevention patients 
without coronary artery disease and secondary prevention patients with coronary 
artery disease. Age range 10–94 years, median age 58 years.
Abbreviations: HDL, high-density lipoprotein; NMR, nuclear magnetic resonance; 
NER/S, extended-release niacin-simvastatin; N, number of patients.
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medium to large. Along with previous results from the same 
study population, which showed that NER/S produced greater 
percent reductions in number of atherogenic LDL particles, 
very low-density lipoprotein (VLDL) and chylomicron par-
ticles, greater increases in particle size for LDL and VLDL, 
and a significant increase of apoprotein A-I levels by 7.2-
fold compared with atorvastatin,19 these effects of NER/S 
demonstrated favorable overall changes in both atherogenic 
and antiatherogenic lipoprotein particles and apolipoproteins. 
Further insights into the effects of niacin extended-release on 
HDL particles should come with the results from an ongoing 
nuclear magnetic resonance substudy of AIM-HIGH (Athero-
thrombosis Intervention in Metabolic Syndrome with Low 
HDL Cholesterol/High Triglyceride and Impact on Global 
Health Outcomes) patients.24
Lipoprotein heterogeneity in structure and particle sub-
class distribution profiles largely reflect changes in lipid 
metabolism and lipoprotein particle maturation reactions. 
In patients with atherogenic dyslipidemia and insulin resis-
tance, there is excessive production and secretion of large 
triglyceride-rich VLDL1 particles by the liver.25 If this is 
accompanied by a lipoprotein lipase deficiency state (as 
occurs, for example, in patients with insulin resistance or 
loss of function mutations in the gene for lipoprotein lipase), 
cholesteryl ester transfer protein catalyzes the transfer of 
  triglycerides out of VLDL in exchange for cholesteryl ester 
from LDL and HDL particles. As these latter particles become 
progressively more enriched with triglycerides, they become 
better substrates for lipolysis by hepatic lipase. Hepatic 
lipase activity produces increased numbers of small, dense 
LDL particles and promotes the catabolism and elimination 
of HDL particles. HDL catabolism results in lower serum 
levels of HDL cholesterol and HDL2 and a larger number of 
HDL3.26 In the setting of excess triglyceride loading, HDL3 
particles do not mature and are highly prone to catabolism 
and elimination by the kidney.
A widely held view is that large HDL2 particles are 
atheroprotective.27 The role of HDL3 particles in prevent-
ing atherogenesis on the other hand is less clear.27,28 Some 
studies have reported that HDL3 is significantly associated 
with coronary heart disease, particularly in patients with 
metabolic syndrome because small HDL particles coincide 
with low HDL cholesterol levels and can be functionally 
compromised in patients with metabolic syndrome.4,16 Other 
studies associate the small HDL3 particle with atheroprotec-
tive functions, including an ability to mature into larger HDL2 
and promote reverse cholesterol transport, and to antagonize 
and inhibit inflammation and oxidation within blood vessel 
walls.29–31 Discordance in these data may reflect the complex 
relationships between HDL subclasses, methods of fraction-
ation, physiological versus pathological conditions (such as 
metabolic diseases or presence of coronary artery disease), 
or treatment effects with different lipid-modifying drugs. 
Nevertheless, niacin therapy results in a shift from small to 
large HDL particles, suggesting that niacin promotes more 
lipidation and maturation of HDL particles.32
Several cardiovascular outcomes and imaging studies 
with extended-release niacin in combination with a statin, 
such as HATS (HDL-Atherosclerosis Treatment Study) and 
ARBITER-6-HALTS (Arterial Biology for the Investigation 
of the Treatment Effects of Reducing Cholesterol 6-HDL 
and LDL Treatment Strategies in Atherosclerosis), have 
shown favorable effects on hard clinical outcomes or on 
surrogate endpoints (such as carotid intima media thickness) 
in patients at high risk and on statin therapy.33,34 However, 
the recent premature termination of the AIM-HIGH study 
due to futility raised the question about whether adding 
extended-release niacin is an effective treatment strategy 
for reducing the risk of cardiovascular events in patients 
with established cardiovascular disease and already very low 
LDL cholesterol (mean 71 mg/dL) and non-HDL cholesterol 
(mean 106 mg/dL) levels on statin or statin/ezetimibe therapy. 
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Figure 2 Distribution of HDL particles in groups treated with NER/S (2000/40 mg/day) 
combination  therapy  and  atorvastatin  monotherapy  (40  mg/day)  at  baseline  and 
week 12. The difference in HDL particle size distribution at week 12 between NER/S 
and atorvastatin after adjusting for HDL particle size at baseline is highly significant 
(P , 0.0001). Size ranges of HDL particle subclasses were large (8.8–13 nm), medium 
(8.2–8.8 nm), and small (7.3–8.2). The P valuea is from the Cochran–Mantel–Haenszel 
test and is shown for significant comparison in HDL particle size distribution between 
NER/S combination therapy and atorvastatin monotherapy. 
Abbreviations: HDL, high-density lipoprotein; NER/S, extended-release niacin-
simvastatin.
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Despite such a debate, use of NER/S in certain patient 
  populations affords an opportunity for comprehensive man-
agement of all modifiable lipid risk factors in the prevention/
treatment of cardiovascular disease. Advantages of such 
combination therapy may include its use in patients needing 
treatment for the atherogenic lipid triad in insulin resistance, 
type 2 diabetes, and in cardiovascular disease, in patients who 
need additional LDL cholesterol and/or non-HDL cholesterol 
reduction following implementation of the maximum dose 
of statins, and the use of lower doses of statins in patients 
who cannot tolerate higher doses because of adverse events 
(eg, myopathy).
In conclusion, treatment with NER/S resulted in a numeri-
cally greater increase in numbers of large HDL particles, 
and a significantly greater decrease in small HDL particles 
compared with atorvastatin monotherapy. In addition, NER/S 
treatment resulted in a significant change in HDL particle 
size distribution from small and medium to large. In patients 
with hyperlipidemia or dyslipidemia, NER/S was associated 
with significant improvements in multiple components of the 
lipid profile, including HDL cholesterol.
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